Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPAHCT-FUL long-term extension safety study of AV-101 in PAH
2021-006864-25Phase 3Active
- Sponsor
- Aerovate Therapeutics
- Start
- Aug 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of 4-chlorokynurenine in pulmonary arterial hypertension (PAH), sponsored by Aerovate Therapeutics. Primary endpoint: Safety and tolerability of AV-101. Started Aug 2022; status: active.
02
Drugs
4-chlorokynurenine
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2021-006864-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006864-25.